Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

Abstract

Biallelic <i>BRCA1/2</i> alterations were associated with elevated gLOH in diverse cancer types, including those not traditionally associated with <i>BRCA1/2</i> cancer syndromes. Biomarker development for PARP inhibitors should integrate methods to distinguish biallelic from monoallelic <i>BRCA1/2</i> status, and biallelic <i>BRCA1/2</i> alteration should be broadly evaluated across cancer types as a biomarker for underlying HRD and PARP inhibitor sensitivity.